Reviewer’s Comment: While invasive disease free survival is an accepted endpoint for approval in adjuvant breast cancer trials, there are varied definitions of DFS. The breast cancer community developed and published the STEEP criteria in 2007 by Hudis et al. The magnitude of benefit varies between trials with each application taking into account a benefit-risk assessment. The ExteNET trial used slightly different definition from the STEEP iDFS criteria, which are defined as the following: